Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma

K. Borankova, M. Krchniakova, LYW. Leck, A. Kubistova, J. Neradil, PJ. Jansson, MD. Hogarty, J. Skoda

. 2023 ; 14 (11) : 747. [pub] 20231116

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Mitochondria are central for cancer responses to therapy-induced stress signals. Refractory tumors often show attenuated sensitivity to apoptotic signaling, yet clinically relevant molecular actors to target mitochondria-mediated resistance remain elusive. Here, we show that MYC-driven neuroblastoma cells rely on intact mitochondrial ribosome (mitoribosome) processivity and undergo cell death following pharmacological inhibition of mitochondrial translation, regardless of their multidrug/mitochondrial resistance and stem-like phenotypes. Mechanistically, inhibiting mitoribosomes induced the mitochondrial stress-activated integrated stress response (ISR), leading to downregulation of c-MYC/N-MYC proteins prior to neuroblastoma cell death, which could be both rescued by the ISR inhibitor ISRIB. The ISR blocks global protein synthesis and shifted the c-MYC/N-MYC turnover toward proteasomal degradation. Comparing models of various neuroectodermal tumors and normal fibroblasts revealed overexpression of MYC proteins phosphorylated at the degradation-promoting site T58 as a factor that predetermines vulnerability of MYC-driven neuroblastoma to mitoribosome inhibition. Reducing N-MYC levels in a neuroblastoma model with tunable MYCN expression mitigated cell death induction upon inhibition of mitochondrial translation and functionally validated the propensity of neuroblastoma cells for MYC-dependent cell death in response to the mitochondrial ISR. Notably, neuroblastoma cells failed to develop significant resistance to the mitoribosomal inhibitor doxycycline over a long-term repeated (pulsed) selection. Collectively, we identify mitochondrial translation machinery as a novel synthetic lethality target for multidrug-resistant MYC-driven tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000659
003      
CZ-PrNML
005      
20240213093316.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41419-023-06278-x $2 doi
035    __
$a (PubMed)37973789
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Borankova, Karolina $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic $1 https://orcid.org/0000000324068109
245    10
$a Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma / $c K. Borankova, M. Krchniakova, LYW. Leck, A. Kubistova, J. Neradil, PJ. Jansson, MD. Hogarty, J. Skoda
520    9_
$a Mitochondria are central for cancer responses to therapy-induced stress signals. Refractory tumors often show attenuated sensitivity to apoptotic signaling, yet clinically relevant molecular actors to target mitochondria-mediated resistance remain elusive. Here, we show that MYC-driven neuroblastoma cells rely on intact mitochondrial ribosome (mitoribosome) processivity and undergo cell death following pharmacological inhibition of mitochondrial translation, regardless of their multidrug/mitochondrial resistance and stem-like phenotypes. Mechanistically, inhibiting mitoribosomes induced the mitochondrial stress-activated integrated stress response (ISR), leading to downregulation of c-MYC/N-MYC proteins prior to neuroblastoma cell death, which could be both rescued by the ISR inhibitor ISRIB. The ISR blocks global protein synthesis and shifted the c-MYC/N-MYC turnover toward proteasomal degradation. Comparing models of various neuroectodermal tumors and normal fibroblasts revealed overexpression of MYC proteins phosphorylated at the degradation-promoting site T58 as a factor that predetermines vulnerability of MYC-driven neuroblastoma to mitoribosome inhibition. Reducing N-MYC levels in a neuroblastoma model with tunable MYCN expression mitigated cell death induction upon inhibition of mitochondrial translation and functionally validated the propensity of neuroblastoma cells for MYC-dependent cell death in response to the mitochondrial ISR. Notably, neuroblastoma cells failed to develop significant resistance to the mitoribosomal inhibitor doxycycline over a long-term repeated (pulsed) selection. Collectively, we identify mitochondrial translation machinery as a novel synthetic lethality target for multidrug-resistant MYC-driven tumors.
650    _2
$a lidé $7 D006801
650    12
$a umělé letální mutace $7 D000072020
650    _2
$a protoonkogenní proteiny c-myc $x genetika $x metabolismus $7 D016271
650    _2
$a apoptóza $7 D017209
650    _2
$a signální transdukce $7 D015398
650    12
$a neuroblastom $x farmakoterapie $x genetika $x metabolismus $7 D009447
650    _2
$a protoonkogen n-myc $x genetika $x metabolismus $7 D000071447
650    _2
$a nádorové buněčné linie $7 D045744
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krchniakova, Maria $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic
700    1_
$a Leck, Lionel Y W $u Cancer Drug Resistance & Stem Cell Program, School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St. Leonards, NSW, 2065, Australia
700    1_
$a Kubistova, Adela $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500, Brno, Czech Republic
700    1_
$a Neradil, Jakub $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic $1 https://orcid.org/0000000167817099 $7 xx0079539
700    1_
$a Jansson, Patric J $u Cancer Drug Resistance & Stem Cell Program, School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St. Leonards, NSW, 2065, Australia $1 https://orcid.org/000000029322653X
700    1_
$a Hogarty, Michael D $u Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA $u Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Skoda, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500, Brno, Czech Republic. jan.skoda@sci.muni.cz $u International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic. jan.skoda@sci.muni.cz $1 https://orcid.org/0000000292928177
773    0_
$w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 14, č. 11 (2023), s. 747
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37973789 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093313 $b ABA008
999    __
$a ok $b bmc $g 2049354 $s 1210353
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c 11 $d 747 $e 20231116 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...